Showing results (51-60 of 79) with videos related to
Sort By:
Pageof 8
International Journal of Surgical Pathology|April 25, 2022
The Search for the Optimal cut-off Value of p53-Immunohistochemistry to Predict Prognosis of Invasive Bladder Cancer: A Multi-Center, Multi-Laboratory AnalysisLaura S Mertens, Francesco Claps, Roman Mayr, et al.European Journal of Cancer (Oxford, England : 1990)|September 11, 2022
Chemotherapy following immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinomaLucie Meynard, Derek Dinart, Blandine Delaunay, et al.The Oncologist|May 17, 2023
Hypofractionated Stereotactic Re-irradiation and Anti-PDL1 Durvalumab Combination in Recurrent Glioblastoma: STERIMGLI Phase I ResultsDamien Pouessel, Soléakhéna Ken, Valérie Gouaze-Andersson, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 14, 2025
Safety and Efficacy of Neoadjuvant Durvalumab Plus Gemcitabine/Cisplatin or Carboplatin in Patients With Operable High-Risk Upper Tract Urothelial Carcinoma: The iNDUCT-GETUG V08 TrialNadine Houédé, Thierry Chevallier, François Audenet, et al.Future Oncology (London, England)|April 29, 2024
A plain language summary of the TROPHY-U-01 study: sacituzumab govitecan use in people with locally advanced or metastatic urothelial cancerYohann Loriot, Arash Rezazadeh Kalebasty, Aude Fléchon, et al.European Journal of Cancer (Oxford, England : 1990)|March 17, 2017
A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU studyAlain Ravaud, Christelle de la Fouchardière, Philippe Caron, et al.European Urology Oncology|October 24, 2024
Real-world Study of Avelumab First-line Maintenance Treatment in Patients with Advanced Urothelial Carcinoma in France: Overall Results from the Noninterventional AVENANCE Study and Analysis of Outcomes by Second-line TreatmentPhilippe Barthélémy, Constance Thibault, Aude Fléchon, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 23, 2024
Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3Petros Grivas, Damien Pouessel, Chandler H Park, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 26, 2026
Neoadjuvant Durvalumab ± Tremelimumab in Combination With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Muscle-Invasive Bladder Carcinoma: Results of the Phase I/II NEMIO StudyConstance Thibault, Mostefa Bennamoun, Aude Fléchon, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 30, 2021
TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint InhibitorsScott T Tagawa, Arjun V Balar, Daniel P Petrylak, et al.Pageof 8